Twenty Years of Clinical Intelligence. Now Productized.
Mere transforms Traditional Chinese Medicine protocols into adaptive, data-driven supplementation. Measure outcomes. Adapt formulas. Close the loop that the $60B supplement industry has never closed.
0+
Years Clinical Infrastructure
0+
Practitioner Alumni
0%
AI Concordance Rate
$0.00
Contribution Margin
$60 Billion in Products. Zero Feedback.
The supplement industry sells billions of dollars worth of static formulas every year. None of them adapt. None of them measure whether they work. And 68-75% of subscribers abandon within 90 days because they have no reason to believe otherwise.
Practitioners know how to deliver outcomes. They have for centuries. But clinical protocols cannot scale beyond the four walls of a clinic. The gap between what works in practice and what reaches consumers has never been bridged.
Mere exists because we spent twenty years inside that gap.
One Platform. Four Steps. Every 30 Days.
Mere is the first adaptive wellness platform that closes the loop between intervention and measurable outcome. No competitor combines clinical protocols, proprietary hardware, and closed-loop data.
Measure
Mere Pulse
Captures arterial pulse waveform every 20 minutes. Tri-wavelength PPG tracks HRV, SpO₂, and autonomic balance continuously.
Interpret
NORA AI
Translates biometric signals into organ-function trend indices. 92% concordance with expert TCM practitioners in N=200 pilot.
Deliver
NanoActives
Patented nano-microbeads deliver targeted botanical protocols. hGMP manufacturing with lot-level traceability.
Adapt
Mere App
Reviews response data and refines the next formula. The loop repeats every 30 days. The data compounds.
General wellness; non-diagnostic. NanoActives are structured under DSHEA as dietary supplements with structure/function claims.
Infrastructure Others Would Spend a Decade Building.
1,000+
Practitioner Alumni
VUIM trained hundreds of practitioners annually across 20+ states. These are not cold leads. They are practitioners who already trust the founders and serve high-intent patient populations.
3.1M+
Prescriptions Fulfilled
Okchundang, a strategic equity investor, operates four hGMP production lines with current capacity of 50,000 units per month. Fifteen years of R&D behind the patented cyclodextrin capture process.
92%
AI Concordance
NORA AI achieved 92% concordance with expert TCM practitioners in an N=200 clinical pilot. Dual encoders fuse tongue imaging and pulse records to deliver organ-function trend indices in under 5 seconds.
$1.0M Pre-Seed SAFE
$9M post-money valuation cap
Mere is raising to prove retention through its clinic network, scale practitioner activation to 400 by Q1 2027, and position for a Seed round with validated unit economics and cohort data.
28%
Manufacturing & Inventory
29%
Product & Engineering
24%
Marketing & Content
19%
Working Capital & Operations